Strategies to Improve Vaccines for the Neonate - Novel vaccine formulations can provide more effective immune protection to newborns. - BioPharm International

ADVERTISEMENT

Strategies to Improve Vaccines for the Neonate
Novel vaccine formulations can provide more effective immune protection to newborns.


BioPharm International


ABSTRACT


Background image: Vaccine & Infectious Disease Organization
Aside from clean water, vaccination has proven to be the most effective means of controlling infectious diseases. Current vaccines technologies include live attenuated vaccines, inactivated vaccines, vectored vaccines, and DNA vaccines. Many challenges still remain including immunization of the neonate, delivery of the vaccine via the mucosal surfaces, and vaccination against chronic infections. Some of the novel concepts to overcome these challenges are based on the use of adjuvants that can induce both innate and acquired immunity or that can target the vaccine to specific immune cells, such as dendritic cells. This article highlights some of these strategies to develop novel vaccine formulations for the neonate.

The use of vaccines dates back to Jenner and Pasteur, who first described the concept of vaccination more than 200 years ago. Since then, vaccines have been used successfully in humans and animals, and aside from clean water represent the most effective means of controlling systemic, respiratory, and gastrointestinal infections in both humans and animals.

Adjuvants: Important Components of Vaccines

Adjuvants are important components of vaccines. They provide an additional stimulus for the immune system, which typically results in stronger immune responses, and can assist in delivering or even targeting of the vaccine. Adjuvants represent a wide variety of molecules and formulations including cell-wall components, alum, QuilA, immunostimulatory complexes (ISCOMs), carbomers, liposomes, and oil-in water emulsions, to name a few. Many of these adjuvants have been developed empirically without an exact understanding of their mechanisms of action. Recent research, however, has provided insight into the activation of the immune system by pathogen recognition receptors, including toll like receptors, C-type lectins, mannose-receptors, and nucleotide-binding oligomerization domain (NOD)-like receptors. These receptors typically recognize highly conserved molecular pattern in pathogens such as bacterial DNA, lipopolysaccharide, or flagellin1,2 and activation often leads to increased NF-κB and/or type I interferon (IFN) production, which can result in up-regulation of chemokines and cytokines needed for a variety of immune functions including recruitment of immune cells to the site of immunization, activation and maturation of dendritic cells, and improved presentation of the antigen.3–5 These events constitute the innate immune response phase, which serves to 1.) contain and eradicate pathogens, and 2.) induce an appropriate adaptive immune response to eliminate infection and prevent reccurrence. Thus, by signaling through pathogen recognition receptors, adjuvants can stimulate both innate and acquired immunity resulting in stronger and longer lasting immune responses to vaccination.

Immune responses elicited by vaccines can be divided into innate and acquired immune responses. Innate immune responses occur within hours of infection or vaccination and are characterized by upregulation of chemokines and cytokines, typically providing a pro-inflammatory environment at the site of immunization. Other innate immune molecules include host defense peptides, also called cationic antimicrobial peptides, complement, and acute phase proteins, which together can recruit and activate dendritic cells to provide a link with the acquired immune response.5 The latter is characterized by the presence of antibodies and cytotoxic T cells, both of which are highly antigen-specific and which recognize very specific structures of the pathogen.

While vaccination in the past traditionally has focused on the induction of the acquired immune response, more recent approaches are focused on stimulating both innate and acquired immunity. In fact, it has become clear now that the innate immune response sets the stage for the acquired immune response, and thus, novel immunomodulators are being used as vaccine adjuvants that can link both innate and specific immunity to enhance the immune responses following vaccination.

Vaccination of the Newborn

Enhancing and modulating immune responses is particularly important in neonates, as infants and young children are highly susceptible to many diseases. When compared to the adult immune system, the neonatal immune system displays a number of functional differences, including its bias towards a Th2-type immune response, delayed germinal center development, shorter lifespan of plasma cells, fewer T-helper cells, and functionally impaired antigen-presenting cells. Together, these functional differences represent a great challenge for the development of effective vaccines for the newborn. Furthermore, potential interference with maternally-derived antibodies makes most vaccines less effective in the neonate.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

EMA Warns of Falsified Herceptin Vials
April 16, 2014
Mallinckrodt to Acquire Questcor Pharmaceuticals
April 16, 2014
American CryoStem and Rutgers University File Joint Patent on Stem Cell Platform
April 11, 2014
Center for Biologics Evaluation and Research Relocates
April 11, 2014
PhRMA Report Reveals Growth Trajectories and Policy Factors Affecting Biopharmaceutical Growth
April 11, 2014
Author Guidelines
Source: BioPharm International,
Click here